Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response

BACKGROUND: Minimally invasive radiofrequency ablation (RFA) is used as a first-line treatment option for hepatocellular cancer (HCC) with the weaknesses of incomplete ablation, tumor recurrence, and inferior outcomes. To overcome this limitation, we proposed to develop sunitinib-RFA integrated ther...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Qi, Xiaoqiang, Yang, Ming, Ma, Lixin, Sauer, Madeline, Avella, Diego, Kaifi, Jussuf T, Bryan, Jeffrey, Cheng, Kun, Staveley-O’Carroll, Kevin F, Kimchi, Eric T, Li, Guangfu
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7594543/
https://ncbi.nlm.nih.gov/pubmed/33115942
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001038
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados